Metastatic Renal Cell Carcinoma in Paranasal Sinus for which Periodic Drug Withdrawal Schedule of Axitinib was Effective : A Case Report

DOI HANDLE Web Site PubMed Open Access
  • Arai Yuichi
    The Department of Urology, National Defense Medical College
  • Ito Keiichi
    The Department of Urology, National Defense Medical College
  • Tachi Kazuyoshi
    The Department of Urology, National Defense Medical College
  • Koga Akio
    The Department of Urology, National Defense Medical College
  • Shinchi Yusuke
    The Department of Urology, National Defense Medical College
  • Masunaga Ayako
    The Department of Urology, National Defense Medical College
  • Isono Makoto
    The Department of Urology, National Defense Medical College
  • Asano Tomohiko
    The Department of Urology, National Defense Medical College

Bibliographic Information

Other Title
  • アキシチニブの休薬スケジュールが有効であった腎細胞癌副鼻腔転移の1例
  • アキシチニブ ノ キュウヤク スケジュール ガ ユウコウ デ アッタ ジンサイボウガン フクビコウ テンイ ノ 1レイ

Search this article

Abstract

A 73-year-old male patient underwent a right nephrectomy for renal cell carcinoma in 2008, and interferon-alpha was initiated as adjuvant treatment. Computed tomography (CT) scans showed lymphadenopathy above the left diaphragm, and treatment with interferon-2 was subsequently initiated in 2009. Nasal bleeding manifested in February 2010, and CT scans showed a soft-tissue density mass mainly located in the ethmoid sinus. A biopsy of the lesion was performed, and metastatic renal cell carcinoma was diagnosed. Treatment with sorafenib was consequently initiated and the paranasal metastasis showed a temporary partial response (PR). However, the metastatic lesion increased in size and caused repeated nasal bleeding that required blood transfusion. Although treatment with everolims was initiated, adverse events, such as rush, hypertensionnemia, and anemia due to nasal bleeding, developed. Treatment with axitinib was subsequently initiated. However, because adverse events, such as severe diarrhea, renal dysfunction and proteinuria manifested, the dose of axitinib was gradually decreased, and a periodic drug withdrawal schedule (11 days on, 3 days off) was finally initiated, which controlled these adverse events. The metastatic lesions showed a PR for 31months following axitinib administration.

Journal

  • 泌尿器科紀要

    泌尿器科紀要 62 (9), 465-471, 2016-09-30

    泌尿器科紀要刊行会

Keywords

Details 詳細情報について

Report a problem

Back to top